Advertisement
UK markets open in 6 hours 44 minutes
  • NIKKEI 225

    38,923.03
    0.00 (0.00%)
     
  • HANG SENG

    18,403.04
    +323.43 (+1.79%)
     
  • CRUDE OIL

    74.07
    -0.15 (-0.20%)
     
  • GOLD FUTURES

    2,371.00
    +1.70 (+0.07%)
     
  • DOW

    38,571.03
    -115.29 (-0.30%)
     
  • Bitcoin GBP

    53,721.82
    +837.98 (+1.58%)
     
  • CMC Crypto 200

    1,442.67
    -25.26 (-1.72%)
     
  • NASDAQ Composite

    16,828.67
    +93.65 (+0.56%)
     
  • UK FTSE All Share

    4,517.03
    -0.05 (-0.00%)
     

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

Benitec Biopharma Inc.
Benitec Biopharma Inc.

HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.

Presentation Details:
Date: May 13, 2024
Time: 11:00 am EDT
Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer

The Benitec presentation will also be available via live webcast here.

ADVERTISEMENT

Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Investor Relations Contact:

Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com